GlaxoSmithKline plc (LSE/NYSE:GSK) has announced that it has chosen to stop enrollment and vaccination of studies testing its respiratory syncytial virus (RSV) maternal vaccine candidate in women.
The company had announced a voluntary pause of the trials NCT04605159, NCT04980391 and NCT05229068 on February 18.
GSK did not elaborate on the reason for halting the trials.
GSK’s AReSVi 006 Phase 3 trial (NCT04886596) for RSV older adults 60 years and older is ongoing.
GSK shares were down 2.25% to $41.72 in mid-day trading.
Vaccine makers have attempted in vain to create a vaccine for RSV, which CDC links to 14,000 deaths in adults aged 65 years or older annually.
Several companies have RSV vaccine candidates, including Moderna (NASDAQ:MRNA) and Janssen (NYSE:JNJ).